Skip to main content

Advertisement

Log in

Changes to upper eyelid orbital fat from use of topical bimatoprost, travoprost, and latanoprost

  • Clinical Investigation
  • Published:
Japanese Journal of Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To confirm the possible mechanism by which topical prostaglandin antiglaucoma drugs cause a deep superior sulcus.

Methods

Among patients who used bimatoprost (Lumigan), latanoprost (Xalatan), or travoprost (Travatan) and who developed a deep upper lid sulcus, 18 eyes of 11 patients (mean age, 58.2 ± 8.9 years) were studied. Seven patients were binocular users of one of the eye drops and four were monocular users. Preaponeurotic orbital fat was obtained, and the mean adipocyte density compared. Results: In the four monocular users, mean adipocyte density of treated eyes was 1758.21 ± 158.15 cells/mm2, and that of untreated eyes was 1258.73 ± 127.54 cells/mm2. This difference was statistically significant (P = 0.04), suggesting that the adipocytes were atrophied in the treated eyes. The mean adipocyte density of the bimatoprost group was 2073.35 ± 184.89 cells/mm2, that of the travoprost group was 1623.46 ± 218.99 cells/mm2, and that of the latanoprost group was 1468.20 ± 113.44 cells/mm2. The densities of the bimatoprost and travoprost groups, but not of the latanoprost group (P = 0.75), were significantly different from that of the untreated group (P < 0.001).

Conclusions

Fat atrophy can be considered a mechanism of upper eyelid sulcus deepening in patients using topical prostaglandin analogs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Krauss, AH, Woodward DF. Update on the mechanism of action of bimatoprost: a review and discussion of new evidence. Surv Ophthalmol 2004;49:S5–11.

    Article  PubMed  Google Scholar 

  2. Hylton C, Robin AL. Update on prostaglandin analogs. Curr Opin Ophthalmol 2003;14:65–69.

    Article  PubMed  Google Scholar 

  3. Eisenberg DL, Toris CB, Camras CB. Bimatoprost and travoprost: a review of recent studies of two new glaucoma drugs. Surv Ophthalmol 2002;47:S105–115.

    Article  PubMed  Google Scholar 

  4. DuBiner H, Cooke D, Dirks M, Stewart WC, VanDenburgh AM, Felix C. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost. Surv Ophthalmol 2001;45:S353–360.

    Article  PubMed  Google Scholar 

  5. Miyake K, Ibaraki N. Prostaglandins and cystoid macular edema. Surv Ophthalmol 2002;47:S203–218.

    Article  PubMed  Google Scholar 

  6. Vogel R, Strahlman E, Rittenhouse KD. Adverse events associated with commonly used glaucoma drugs. Int Ophthalmol Clin 1999;39:107–124.

    Article  CAS  PubMed  Google Scholar 

  7. Easthope SE, Perry CM. Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension. Drug Aging 2002;19:231–248.

    Article  CAS  Google Scholar 

  8. Peplinski LS, Albiani Smith K. Deepening of lid sulcus from topical bimatoprost therapy. Optom Vis Sci 2004;81:574–577.

    Article  PubMed  Google Scholar 

  9. Lee JW, Kim DY, Lee YK. Two cases of deepening of the upper lid sulcus from topical bimatoprost therapy. J Korean Ophthalmol Soc 2007;48:332–336.

    Google Scholar 

  10. Filippopoulos T, Paula JS, Torun N, Hatton MP, Pasquale LR, Grosskreutz CL. Periorbital changes associated with topical bimatoprost. Ophthal Plast Reconstr Surg 2008;24:302–307.

    Article  PubMed  Google Scholar 

  11. Tappeiner C, Perren B, Iliev ME, Frueh BE, Goldblum D. Orbital fat atrophy in glaucoma patients treated with topical bimatoprost—can bimatoprost cause enophthalmos? Klin Monbl Augenheilkd 2008;225:443–445.

    Article  CAS  PubMed  Google Scholar 

  12. Yam JC, Yuen NS, Chan CW. Bilateral deepening of upper lid sulcus from topical bimatoprost therapy. J Ocul Pharmacol Ther 2009;25:471–472.

    Article  CAS  PubMed  Google Scholar 

  13. Yang HK, Park KH, Kim TW, Kim DM. Deepening of eyelid superior sulcus during topical travoprost treatment. Jpn J Ophthalmol 2009;53:176–179.

    Article  CAS  PubMed  Google Scholar 

  14. Casson RJ, Selva D. Lash ptosis caused by latanoprost. Am J Ophthalmol 2005;139:932–933.

    Article  PubMed  Google Scholar 

  15. Rohrich RJ, Coberly DM, Fagien S, Stuzin JM. Current concepts in aesthetic upper blepharoplasty. Plast Reconstr Surg 2004;113:32e–42e.

    Article  PubMed  Google Scholar 

  16. Serrero G, Lepak N. Endocrine and paracrine negative regulators of adipose differentiation. Int J Obes Relat Metab Disord 1996;20:S58–64.

    CAS  PubMed  Google Scholar 

  17. Serrero G, Lepak NM. Prostaglandin F2alpha receptor (FP receptor) agonists are potent adipose differentiation inhibitors for primary culture of adipocyte precursors in defined medium. Biochem Biophys Res Commun 1997;233:200–202.

    Article  CAS  PubMed  Google Scholar 

  18. Reginato MJ, Krakow SL, Bailey ST, Lazar MA. Prostaglandins promote and block adipogenesis through opposing effects on peroxisome proliferator-activated receptor gamma. J Biol Chem 1998;273:1855–1858.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jung-Il Moon.

About this article

Cite this article

Park, J., Cho, H.K. & Moon, JI. Changes to upper eyelid orbital fat from use of topical bimatoprost, travoprost, and latanoprost. Jpn J Ophthalmol 55, 22–27 (2011). https://doi.org/10.1007/s10384-010-0904-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10384-010-0904-z

Keywords

Navigation